Among these PTMs exhibiting consistent effects on chemoradiation resistance (Figure 1C), several oncogenic modifiers, including SMYD3, PRMT3, PRMT5, and FBL, were noted, which have been previously implicated in multidrug resistance across various cancers.[11, 13, 14] Given our prior demonstration of PRMT3's central role in oxaliplatin resistance and immunotherapy evasion in hepatocellular carcinoma,[13] we elected to concentrate our investigation on PRMT3. This evidence concerns the gene PRMT5 and cancer.